Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001–2010

[11] Thompson AJ(2012)Placebo-controlled phase 3 study of oral BG-12 for relapsing mutiple sclerosis N Engl J Med 367 1098-1107

[12] Johnson KP(2003)Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS Neurology 61 551-554

[13] Brooks BR(2011)Adherence to disease-modifying therapies in Spanish patients with relapsing multiple sclerosis: two-year interim results of the Global Adherence Project Eur Neurol 65 59-67

[14] Cohen JA(2005)Factors leading patients to discontinue multiple sclerosis therapies J Am Pharm Assoc 45 371-375

[15] Ford CC(2009)Association of prescription abandonment with cost share for high-cost specialty pharmacy medications J Manag Care Pharm 15 648-658

[16] Goldstein J(2010)Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence Patient Prefer Adherence 4 1-9

[17] Lisak RP(2005)Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis Mult Scler 11 306-309

[18] Myers LW(2009)Factors that influence adherence with disease-modifying therapy in MS J Neurol 256 568-576

[19] Panitch HS(2009)Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis Rehab Psychol 54 116-121

[20] Rose JW(2007)Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population Curr Med Res Opin 23 1209-1215

[11] Thompson AJ(2012)Placebo-controlled phase 3 study of oral BG-12 for relapsing mutiple sclerosis N Engl J Med 367 1098-1107

[12] Johnson KP(2003)Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS Neurology 61 551-554

[13] Brooks BR(2011)Adherence to disease-modifying therapies in Spanish patients with relapsing multiple sclerosis: two-year interim results of the Global Adherence Project Eur Neurol 65 59-67

[14] Cohen JA(2005)Factors leading patients to discontinue multiple sclerosis therapies J Am Pharm Assoc 45 371-375

[15] Ford CC(2009)Association of prescription abandonment with cost share for high-cost specialty pharmacy medications J Manag Care Pharm 15 648-658

[16] Goldstein J(2010)Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence Patient Prefer Adherence 4 1-9

[17] Lisak RP(2005)Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis Mult Scler 11 306-309

[18] Myers LW(2009)Factors that influence adherence with disease-modifying therapy in MS J Neurol 256 568-576

[19] Panitch HS(2009)Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis Rehab Psychol 54 116-121

[20] Rose JW(2007)Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population Curr Med Res Opin 23 1209-1215